Journal of Cancer Research and Practice最新文献

Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology 台湾肿瘤分子委员会专家共识：台湾肿瘤学会与台湾病理学会联合立场文件

Journal of Cancer Research and Practice Pub Date : 2024-01-19 DOI: 10.4103/ejcrp.ejcrp-d-23-00050

Ming-Huang Chen, Wan-Shan Li, Bin-Chi Liao, Chiao-En Wu, Chien-Feng Li, Chia Hsieh, Feng-Che Kuan, Huey-En Tzeng, Jen-Fan Hang, Nai-Jung Chiang, Tse-Ching Chen, Tom Wei-Wu Chen, J. W. Chang, Yao-Yu Hsieh, Yen-Lin Chen, Yi-Chen Yeh, Yi-Hsin Liang, Yu-Li Su, Chiung-Ru Lai, James Chih-Hsin Yang

{"title":"Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology","authors":"Ming-Huang Chen, Wan-Shan Li, Bin-Chi Liao, Chiao-En Wu, Chien-Feng Li, Chia Hsieh, Feng-Che Kuan, Huey-En Tzeng, Jen-Fan Hang, Nai-Jung Chiang, Tse-Ching Chen, Tom Wei-Wu Chen, J. W. Chang, Yao-Yu Hsieh, Yen-Lin Chen, Yi-Chen Yeh, Yi-Hsin Liang, Yu-Li Su, Chiung-Ru Lai, James Chih-Hsin Yang","doi":"10.4103/ejcrp.ejcrp-d-23-00050","DOIUrl":"https://doi.org/10.4103/ejcrp.ejcrp-d-23-00050","url":null,"abstract":"\u0000 \u0000 \u0000 The Taiwan Oncology Society (TOS) and the Taiwan Society of Pathology (TSP) have collaborated to present a joint position paper on the molecular tumor boards (MTBs) within the medical institutions of Taiwan.\u0000 \u0000 \u0000 \u0000 To raise awareness of MTBs among health-care professionals, policymakers, and the public, a total of 20 experts from TOS and TSP formulated a joint consensus statement through a voting process.\u0000 \u0000 \u0000 \u0000 The joint statement proposes key recommendations: (1) MTB discussions encompass diverse molecular analyses including next-generation sequencing (NGS), RNA sequencing, whole-exon sequencing, and whole-genomic sequencing addressing relevant genomic changes, tumor mutation burden, microsatellite instability, and specific biomarkers for certain cancers. (2) MTB meetings should involve multidisciplinary participants who receive regular updates on NGS-related clinical trials. (3) Prioritize discussing cases with unique clinical needs, gene alterations lacking treatments, untreatable neoplasms, or oncogenes unresponsive to targeted therapies. (4) Base MTB discussions on comprehensive patient data, including genetics, pathology, timing of specimen collection, and NGS outcomes. (5) MTBs offer treatment recommendations: standard therapies, off-label use, clinical trials, genetic counseling, and multidisciplinary reviews. (6) MTB effectiveness can be gauged by member composition, case reviews, treatment suggestions, and patient outcomes. Encourage government incentives for MTB engagement.\u0000 \u0000 \u0000 \u0000 The primary aim of this initiative is to promote the advancement of precision oncology in Taiwan.\u0000","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"100 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139612526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A juvenile female with ductal carcinoma In situ arising from a fibroadenoma 一例由纤维腺瘤引起的导管原位癌青年女性

Journal of Cancer Research and Practice Pub Date : 2023-04-01 DOI: 10.4103/ejcrp.eJCRP-D-22-00019

Wan-Yu Hung, Chih-Ling Lee, Chin-Yao Lin

引用次数: 0

Promising response with PI3K inhibitor for a patient with heavily pretreated PIK3CA mutation head-and-neck cancer PI3K抑制剂对重度预处理的PIK3CA突变头颈癌患者有希望的疗效

Journal of Cancer Research and Practice Pub Date : 2023-04-01 DOI: 10.4103/ejcrp.eJCRP-D-22-00018

Ming-Jing Lee, H. Kao

引用次数: 0

Small pancreas neuroendocrine tumors: How small is small? 胰腺小神经内分泌肿瘤:小到什么程度?

Journal of Cancer Research and Practice Pub Date : 2023-04-01 DOI: 10.4103/ejcrp.eJCRP-D-22-00030

M. Chen, Chia Hsieh, Ching-Yao Yang, H. Tsai, Li‐Tzong Chen

引用次数: 0

Unfavorable tumor responses to immunotherapy in the liver: Lessons learned from clinical and preclinical studies 肝脏免疫疗法对肿瘤的不良反应：从临床和临床前研究中吸取的教训

Journal of Cancer Research and Practice Pub Date : 2023-04-01 DOI: 10.4103/ejcrp.eJCRP-D-22-00033

Li‐Chun Lu, G. Feng, Chih-Hung Hsu

{"title":"Unfavorable tumor responses to immunotherapy in the liver: Lessons learned from clinical and preclinical studies","authors":"Li‐Chun Lu, G. Feng, Chih-Hung Hsu","doi":"10.4103/ejcrp.eJCRP-D-22-00033","DOIUrl":"https://doi.org/10.4103/ejcrp.eJCRP-D-22-00033","url":null,"abstract":"Objective: Immunotherapy with immune checkpoint inhibitors (ICIs) has become a standard of care for many malignancies. The tumor microenvironment (TME) varies across different organs and affects tumor initiation, progression, and treatment outcomes. Organ-specific differential responses to ICIs have been observed in various cancers. The underlying mechanisms warrant further investigation. Data Sources and Study Selection: We enrolled relevant clinical and preclinical studies conducted by our groups and others. Current evidence and data were reviewed and future implication was discussed. Results: In patients with advanced hepatocellular carcinoma or esophageal cancer, non-small cell lung cancer, or melanoma with liver metastases, the efficacy of ICI-based therapy was generally lower in the liver than in other organs. The mouse liver cancer study showed that myeloid-derived suppressor cells (MDSCs) might play a role in immunosuppressive TME in the liver as compared to subcutaneous tissues; targeting MDSCs enhanced anti-tumor efficacy in the liver. The metastatic colon cancer models showed that monotherapy with anti-programmed death ligand-1 (PD-L1) antibody was less effective in suppressing tumor growth in the liver than in subcutaneous tissues. Mechanistically, modulation of hepatic innate immune cells was associated with the improved response of anti-PD-L1 antibody in the liver. Conclusion: The relatively unfavorable tumor response to immunotherapy in the liver of various cancers may be attributable to the immunosuppressive hepatic TME. Future comprehensive immune profiling is required to identify key factors and mechanisms in specific organs to overcome immunosuppressive TME, particularly in the liver.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"10 1","pages":"45 - 49"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44668814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bilateral bulky adrenal plasmacytomas with very good response to daratumumab-based therapy 双侧大体积肾上腺浆细胞瘤，对达拉图单抗治疗有很好的反应

Journal of Cancer Research and Practice Pub Date : 2023-04-01 DOI: 10.4103/ejcrp.eJCRP-D-22-00027

Fang Wang, Han-Kuang Hsieh, Tso-fu Wang, Yi-Feng Wu

引用次数: 0

Significance of baseline and changes of tumor markers and neutrophil-to-lymphocyte ratio in predicting overall survival for patients with advanced pancreatic adenocarcinoma: A retrospective analysis 肿瘤标志物和中性粒细胞与淋巴细胞比率的基线和变化在预测晚期胰腺癌患者总生存率中的意义：一项回顾性分析

Journal of Cancer Research and Practice Pub Date : 2023-04-01 DOI: 10.4103/ejcrp.ejcrp-d-22-00036

Makoto Kadokura, Keisuke Tanaka, F. Amemiya, S. Takano, M. Fukasawa, N. Enomoto

{"title":"Significance of baseline and changes of tumor markers and neutrophil-to-lymphocyte ratio in predicting overall survival for patients with advanced pancreatic adenocarcinoma: A retrospective analysis","authors":"Makoto Kadokura, Keisuke Tanaka, F. Amemiya, S. Takano, M. Fukasawa, N. Enomoto","doi":"10.4103/ejcrp.ejcrp-d-22-00036","DOIUrl":"https://doi.org/10.4103/ejcrp.ejcrp-d-22-00036","url":null,"abstract":"Background: The usefulness of various prognostic factors for pancreatic cancer has been reported, but limited studies have focused on these changes during chemotherapy. The purpose of the present study was to investigate the prognostic factors and to evaluate the significance of these changes during chemotherapy in patients with advanced pancreatic cancer (APC). Materials and Methods: We retrospectively analyzed 213 patients with APC who underwent chemotherapy between January 2006 and December 2018 at Kofu Municipal Hospital and University of Yamanashi Hospital. Univariate and multivariate cox regression models were applied to investigate independent prognostic factors. Results: Multivariate analysis revealed that Eastern Cooperative Oncology Group Performance Status 2 (hazard ratio [HR] 4.07, P < 0.01), neutrophil-to-lymphocyte ratio (NLR) ≥3.9 (HR 1.97, P < 0.001), modified Glasgow prognostic score 1–2 (HR 2.77, P < 0.001), carcinoembryonic antigen ≥5.0 (HR 1.44, P = 0.026), carbohydrate antigen 19-9 ≥37 (HR 1.83, P = 0.004), ΔNLR >0 (HR 2.01, P < 0.001), ΔCEA (subtracting the baseline from the start of second cycles of chemotherapy) >0 (HR 1.64, P = 0.002), and ΔCA19-9>0 (HR 1.77, P = 0.002) were independent negative prognostic factors. Conclusion: Baseline and change in tumor markers and NLR are useful in predicting overall survival in APC patients undergoing chemotherapy.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"10 1","pages":"57 - 62"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45428306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pneumothorax during alectinib treatment for a uterine inflammatory myofibroblastic tumor with lung metastasis 阿来替尼治疗子宫炎性肌成纤维细胞肿瘤合并肺转移期间的肺炎

Journal of Cancer Research and Practice Pub Date : 2023-04-01 DOI: 10.4103/ejcrp.eJCRP-D-22-00031

Chang-Ting Lin, Chenhsuan Wu, Hsuan-Ying Huang, Chien-ting Liu

引用次数: 0

Adjuvant chemotherapy in patients with low-risk epithelial ovarian cancer: A Taiwanese cohort study 低风险上皮性卵巢癌症患者辅助化疗的台湾队列研究

Journal of Cancer Research and Practice Pub Date : 2023-04-01 DOI: 10.4103/ejcrp.eJCRP-D-23-00003

Yuan-Ting C. Lo, H. Ku, Cheng-Shyong Chang, Hui-Ju Ch’ang, Chih-Ming Ho, T. Liu, Shih-Min Lin

{"title":"Adjuvant chemotherapy in patients with low-risk epithelial ovarian cancer: A Taiwanese cohort study","authors":"Yuan-Ting C. Lo, H. Ku, Cheng-Shyong Chang, Hui-Ju Ch’ang, Chih-Ming Ho, T. Liu, Shih-Min Lin","doi":"10.4103/ejcrp.eJCRP-D-23-00003","DOIUrl":"https://doi.org/10.4103/ejcrp.eJCRP-D-23-00003","url":null,"abstract":"Background: Whether or not patients with stage I epithelial ovarian cancer (EOC) benefit from postoperative chemotherapy in the Asian population remains unclear. This retrospective cohort study was aimed at investigating the use of adjuvant chemotherapy in clinical practice to treat patients with early-stage EOC considering clinical factors. Materials and Methods: A total of 414 patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IA–IC and grade 1 EOC were enrolled from the Taiwan Cancer Registry. We used multivariable Cox proportional-hazards models to control for clinical factors. The overall survival (OS) and disease-free survival (DFS) were estimated with the Kaplan–Meier method. Results: DFS did not improve significantly for patients with FIGO stage IA/IB EOC receiving adjuvant chemotherapy, with a 10-year DFS rate of 98% and 88% for those with and without adjuvant chemotherapy, respectively (hazard ratio [HR] = 0.41, 95% confidence interval [CI]: 0.05–3.36). OS did not improve significantly for patients with FIGO stage IA/IB EOC with adjuvant chemotherapy (HR = 0.86, 95% CI: 0.18–4.22) or stage IC (HR = 0.50, 95% CI: 0.10–2.45). OS did not differ significantly for patients with optimal (10-year OS: 92% with chemotherapy and 86% without chemotherapy in the log-rank test, P = 0.629) or nonoptimal staging (10-year OS: 73% with chemotherapy and 90% without chemotherapy in the log-rank test, P = 0.959). Conclusion: Adjuvant chemotherapy did not improve the prognosis of patients with low to intermediate-risk EOC and optimal/nonoptimal surgery. This result should be considered in clinical practice.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"10 1","pages":"63 - 70"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49235238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ewing's sarcoma of the small intestine with liver metastasis mimicking gastrointestinal stromal tumor 类似胃肠道间质瘤的小肠尤因肉瘤伴肝转移

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-22-00021

P. Chen, Wan-Ting Li, Chih-Hung Hsu, T. Chen

引用次数: 0